OVERVIEW

New Therapeutic Options for Acute and Chronic Hyperkalemia is organized by the AcademicCME.

Program Dates: January 6th, 2020 - January 5th, 2021

Accreditation:
Credit Designation Statements:
• AcademicCME designates this live material for a maximum of 1.50 AMA PRA Category 1 Credits™.
• AcademicCME designates this live material for a maximum of 1.50 CNE Contact Hour, including 1.50 pharmacotherapeutic contact hours (Provider number P0491).
• AcademicCME designates this continuing education activity for 1.50 CPE Contact Hours (0.15 CEUs) of continuing pharmacy education credit

Program Overview:
This CME/CE program, derived from content presented at the 2019 American Heart Association Scientific Sessions in Philadelphia, Pennsylvania, will highlight new therapeutic options for acute and chronic hyperkalemia. The expert faculty, led by Dr. Charles V. Pollack, Jr., will first provide an introduction and state of the science of hyperkalemia, including risk assessment and disease burden. Recent trial data of both emerged and emerging agents for the treatment of acute and chronic hyperkalemia will be reviewed, and clinical relevance debated through an interactive panel format. The expert faculty will conclude with a review of the role of the interprofessional team in personalized medicine to improve outcomes and quality of life for patients with acute and chronic hyperkalemia.

Learning Objectives
• Assess hyperkalemia risk and disease burden in patients with underlying diseases such as heart failure, diabetes, hypertension, and chronic kidney disease
• Review the recent clinical trial data for the treatment of acute and chronic hyperkalemia to inform clinical decision making
• Improve collaboration among the healthcare team to develop optimal individual treatment strategies for patients with hyperkalemia